drugset

drugset / Trial / NCT04477200

Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

NCT04477200 ↗

Phase 1 Active not recruiting 68 enrolled University of Michigan Rogel Cancer Center National Cancer Institute (NCI) · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

This is a phase 0/1 dose-escalation trial to determine the maximum tolerated dose of Mycophenolate Mofetil (MMF) when administered with radiation, in patients with glioblastoma or gliosarcoma.

Timeline

Start: 2020-08-05
Primary completion: 2025-01-06
Completion: 2027-11-05

Publications

Zhao G, Newbury P, Ishi Y, Chekalin E, Zeng B, Glicksberg BS, Wen A, Paithankar S, Sasaki T, Suri A, Nazarian J, Pacold ME, Brat DJ, Nicolaides T, Chen B, Hashizume R. Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma. Acta Neuropathol Commun. 2022 Oct 23;10(1):150. doi: 10.1186/s40478-022-01463-z.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mycophenolate Mofetil	Small molecule	250 mg	Oral
Subject	Mycophenolate Mofetil	Small molecule	500 mg	Oral
Subject	Mycophenolate Mofetil	Small molecule	1000 mg	Oral
Subject	Mycophenolate Mofetil	Small molecule	1500 mg	Oral
Subject	Mycophenolate Mofetil	Small molecule	2000 mg	Oral
Background	Temozolomide	Small molecule	—	Oral

Indications